Sun Pharma Advanced Research Company Other Announcement
Sun Pharma Advanced Research filed its monitoring agency report on warrant issue proceeds for the quarter ended September 30, 2026. The agency found no deviation from objects.
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
7 announcements with these filters
Sun Pharma Advanced Research filed its monitoring agency report on warrant issue proceeds for the quarter ended September 30, 2026. The agency found no deviation from objects.
Sun Pharma Advanced Research Company Ltd reported revenue from operations of ₹30 Cr (+279.7% YoY) and a net loss of ₹24.4 Cr for Q2 FY27.
SPARC intimated its Board will meet November 2, 2026 to consider Q1 and H1 FY27 unaudited results. Insider trading window stays closed until 48 hours post-declaration.
Sun Pharma Advanced Research Company Ltd has filed its quarterly shareholding pattern under Regulation 31(1)(b) for the quarter ended September 30, 2026.
The company secured a favorable CESTAT order confirming its entitlement to a Rs. 27.51 Crore CENVAT credit refund. This concludes the litigation in the company's favor.
Sun Pharma Advanced Research Company Ltd has filed its quarterly shareholding pattern for the period ended June 30, 2026.
Sun Pharma Advanced Research Company has submitted an application to stock exchanges to reclassify certain members from 'Promoter Group' to 'Public' category.